Business Context and Reporting Period
This Form 8-K Current Report, dated October 26, 2025, covers Organon & Co. (NYSE: OGN). The filing addresses significant corporate governance changes and the results of an Audit Committee investigation into wholesaler sales practices for the product Nexplanon. The investigation covers sales activities in Q4 2022, Q3 and Q4 2024, and Q1 through Q3 2025.
Key Financial Metrics and Material Changes
Revenue Impact: The investigation found that improper sales practices involved asking wholesalers to purchase greater quantities of Nexplanon than demand warranted. These incremental sales represented less than 1% of consolidated revenue for the years ended December 31, 2022 and 2024, and less than 2% for the relevant quarterly periods. Without these practices, revenue for certain periods would have fallen short of guidance and external expectations.
Financial Statement Restatements: The Company has determined there will be no restatement or revision to previously issued financial statements. However, the filing states that the Company's prior assessment of effective internal control over financial reporting (ICFR) as of December 31, 2024, is no longer valid due to one or more material weaknesses.
Debt and Liquidity: The filing text does not provide specific values for debt, liquidity, or cash flow.
Management Changes and Compensation
- Departure: Kevin Ali resigned as Chief Executive Officer and Board member on October 26, 2025, in connection with the investigation. He is not entitled to severance or equity-related retirement benefits.
- Interim CEO: Joseph Morrissey (EVP and Head of Manufacturing & Supply) was appointed Interim CEO. His compensation was adjusted to a $1 million salary, a bonus target of 100% of salary (prorated), and an annual long-term incentive target of $4 million effective next year. He also received a one-time grant of $1 million in restricted stock units.
- Executive Chair: Carrie S. Cox was appointed Executive Chair for an interim period. Compensation has not yet been established.
- Board Changes: Robert Essner was appointed Lead Independent Director, and Helene Gayle, M.D., was appointed to chair the Talent Committee.
Outlook, Risks, and Contingencies
Internal Controls: The Company concluded that the ICFR assessment in its 2024 Form 10-K should no longer be relied upon. PricewaterhouseCoopers LLP's opinion on ICFR effectiveness as of December 31, 2024, is also no longer valid. The Company expects to file amendments to the 2024 Form 10-K and 2025 Q1 and Q2 Form 10-Qs to reflect material weaknesses and correct prior determinations.
Future Filings: The Company intends to timely file its Q3 2025 Form 10-Q. A search committee has been formed to find a permanent CEO replacement.
Risks: Significant risks include the timing of the investigation's completion, potential legal or regulatory actions regarding sales practices, the impact on stock price, and the Company's relationships with investors, employees, and wholesalers.
Investor Verification Checklist
- Verify the timeline for the filing of the amended 2024 Form 10-K and 2025 Q1/Q2 Form 10-Qs.
- Monitor the final results of the Audit Committee investigation and any subsequent regulatory inquiries.
- Review the upcoming Q3 2025 earnings release for updated guidance and revenue figures excluding the impact of improper sales practices.
- Assess the progress of the search for a permanent CEO and the stability of the interim leadership team.
- Confirm the specific nature of the material weaknesses in internal controls once disclosed in the amended filings.